[go: up one dir, main page]

NO20064951L - 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse - Google Patents

1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse

Info

Publication number
NO20064951L
NO20064951L NO20064951A NO20064951A NO20064951L NO 20064951 L NO20064951 L NO 20064951L NO 20064951 A NO20064951 A NO 20064951A NO 20064951 A NO20064951 A NO 20064951A NO 20064951 L NO20064951 L NO 20064951L
Authority
NO
Norway
Prior art keywords
ppar delta
oxadiazole
ones
delta modulators
compounds
Prior art date
Application number
NO20064951A
Other languages
English (en)
Inventor
Stefanie Keil
Jean Merrill
Karen Chandross
Jochen Goerlitzer
Wolfgang Wendler
Daniel G Mcgarry
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20064951L publication Critical patent/NO20064951L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse angår 1, 3, 4-oksadiazaloner, forbindelser med formel I og deres farmasøytisk akseptable salter, stereoisomerer, tautomerer eller solvater derav. Nye forbindelser inkluderer de med formel I, der radikalene er som definert i dokument. Forbindelsene ifølge oppfinnelsen er modulatorer av PPARdelta og derfor nyttige som farmasøytiske midler, spesielt for behandling av demyelineringssykdommer og forstyrrelser i fettsyremetabolismen og glukoseutnyttelsen.
NO20064951A 2004-04-01 2006-10-30 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse NO20064951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55842004P 2004-04-01 2004-04-01
PCT/US2005/010855 WO2005097763A2 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta

Publications (1)

Publication Number Publication Date
NO20064951L true NO20064951L (no) 2006-10-30

Family

ID=34972960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064951A NO20064951L (no) 2004-04-01 2006-10-30 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse

Country Status (15)

Country Link
US (2) US7638539B2 (no)
EP (1) EP1781648A2 (no)
JP (1) JP4813461B2 (no)
CN (1) CN1956984B (no)
AU (1) AU2005230838A1 (no)
BR (1) BRPI0508180A (no)
CA (1) CA2561230A1 (no)
IL (1) IL178166A0 (no)
MA (1) MA28563B1 (no)
NO (1) NO20064951L (no)
NZ (1) NZ549823A (no)
RU (1) RU2365589C2 (no)
SG (1) SG151336A1 (no)
WO (1) WO2005097763A2 (no)
ZA (1) ZA200607852B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375358C2 (ru) * 2004-04-01 2009-12-10 Авентис Фармасьютикалз, Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
EP1781648A2 (en) * 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
ES2386734T3 (es) 2005-12-22 2012-08-28 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-DELTA
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
BR112012007160A2 (pt) 2009-09-30 2018-03-13 Harvard College metodos para modulacao da autofagia por meio da modulacao d eprodutos genicos inibidores da autofagia
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
KR101715127B1 (ko) * 2015-10-30 2017-03-15 한국과학기술연구원 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
CN114195786B (zh) * 2020-09-18 2023-08-22 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
CN114195777B (zh) * 2020-09-18 2023-06-20 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
CA2377246A1 (en) * 1999-06-18 2000-12-28 Ranjit C. Desai Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6506781B1 (en) * 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
RU2375358C2 (ru) * 2004-04-01 2009-12-10 Авентис Фармасьютикалз, Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
EP1781648A2 (en) * 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators

Also Published As

Publication number Publication date
CN1956984A (zh) 2007-05-02
BRPI0508180A (pt) 2007-08-07
SG151336A1 (en) 2009-04-30
IL178166A0 (en) 2006-12-31
MA28563B1 (fr) 2007-04-03
EP1781648A2 (en) 2007-05-09
AU2005230838A1 (en) 2005-10-20
US20070099964A1 (en) 2007-05-03
JP2007531764A (ja) 2007-11-08
US7872032B2 (en) 2011-01-18
ZA200607852B (en) 2008-07-30
JP4813461B2 (ja) 2011-11-09
RU2365589C2 (ru) 2009-08-27
US7638539B2 (en) 2009-12-29
US20090275621A1 (en) 2009-11-05
NZ549823A (en) 2009-12-24
CA2561230A1 (en) 2005-10-20
WO2005097763A3 (en) 2005-12-15
WO2005097763A2 (en) 2005-10-20
CN1956984B (zh) 2010-06-09
RU2006138494A (ru) 2008-05-10

Similar Documents

Publication Publication Date Title
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
NO20090328L (no) Nye forbindelser 385
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20082496L (no) Pyrazinderivater
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20053748L (no) Pyrrolopyridazinderivater.
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
NO20062135L (no) Fenylderivater som PPAR-agonister
NO20090327L (no) Nye forbindelser 384
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
NO20063928L (no) Substituerte kinolinforbindelser
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20055977L (no) Nye benzimidazolderivater
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application